Who is sponsoring NCT02473367?

NCT02473367 is sponsored by Merck Sharp & Dohme LLC.

What condition does NCT02473367 study?

NCT02473367 studies HIV Infection.

What drugs are being tested in NCT02473367?

Interventions: Raltegravir 1200 mg, TUMS, Leader Antacid.

What is the status of NCT02473367?

NCT02473367 is currently COMPLETED.

Last reviewed 2018-08-27 · How we verify

The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)

NCT02473367 PHASE1 COMPLETED Results posted

In order to define the safe windows for co-dosing of metal-cation antacids with once daily administered raltegravir, this study will evaluate the effect of both calcium carbonate and magnesium/aluminum hydroxide antacids on the pharmacokinetics of raltegravir, due to dosage of 1200 mg raltegravir in HIV-infected participants already taking 400 mg raltegravir twice daily as part of their HIV treatment regimen.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	PHASE1
Status	COMPLETED
Enrolment	20
Start date	Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Oct 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

HIV Infection

Interventions

Raltegravir 1200 mg
TUMS
Leader Antacid